Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.
NCT06311916
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
312
Enrollment
OTHER
Sponsor class
Conditions
HCC
Interventions
DRUG:
HAIC + Tirelizumab +lenvatinib +liver resection
PROCEDURE:
liver resection
Sponsor
Chen Xiaoping